Once Daily Oral Relugolix Combination Therapy Versus Placebo in Patients With Endometriosis-Associated Pain: Two Replicate Phase 3, Randomised, Double-Blind, Studies (SPIRIT 1 and 2)
rct
OA: closed
CC0
AI-generated summary
The SPIRIT 1 and 2 trials evaluated the efficacy and safety of once-daily oral relugolix combination therapy compared to placebo for treating endometriosis-associated pain.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The author describes the results of a study to examine the effect of three treatment regimens on pain associated with endometriosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (2)
References (3)
Source provenance
- europepmc
- last seen: 2026-08-11T06:11:44.160905+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-08-11T06:09:26.967042+00:00
License: CC0
· commercial use OK